Tag: Drug

Opioid Drug Maker Mallinckrodt Files for U.S. Bankruptcy Protection | Investing News

Reuters

FILE PHOTO: Bottles of prescription painkillers Oxycodone Hydrochloride, 30mg pills, made by Mallinckrodt sit on a counter at a local pharmacy, in Provo, Utah, U.S., April 25, 2017. REUTERS/George Frey/File PhotoReuters

(Reuters) – Mallinckrodt filed for bankruptcy protection on Monday, saddled with lawsuits alleging it helped fuel the U.S. opioid epidemic.

Adding to its woes, the company in March also lost a court battle to avoid paying higher rebates to state Medicaid programs for its top-selling drug.

Mallinckrodt said on Monday it had agreed to pay $1.6 billion over several years to settle opioid-related litigation. About $450 million would be paid as part of its settlement once the company emerged from chapter 11 bankruptcy.

The company would then pay $200 million in the first and second year after its emergence from the bankruptcy, and $150 million subsequently through the seventh year.

Mallinckrodt had agreed to pay $260 million over

Read More

Bristol Myers Expands Heart Drug Business With $13 Billion Deal for MyoKardia | Investing News

(Reuters) – Bristol Myers Squibb Co

said on Monday it would buy MyoKardia Inc

for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

The deal comes close on the heels of Bristol Myers’ $74 billion acquisition of Celgene last year, which was aimed at creating an oncology giant and shielding itself from fierce competition for its cancer immunotherapy, Opdivo, from Merck & Co’s

Keytruda.

Shares of MyoKardia, which have nearly doubled in value this year, surged another 57.8% to $220.31, just shy of the offer of $225 per share.

The deal will also help Bristol Myers reduce some of its dependence on cancer drugs and give it access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten, adding to its existing portfolio of heart drugs that includes blood thinner Eliquis.

Eliquis, which

Read More

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team

AI-POWR™ Driving Big Data Analytics

EDISON, NJ / ACCESSWIRE / October 5, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)(“Hepion”), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced the rollout of a proprietary artificial intelligence (“AI”), machine learning platform called, AI-POWR™.

AI-POWR™ is Hepion’s acronym for Artificial Intelligence – Precision Medicine; Omics that include genomics, proteomics, metabolomics, transcriptomics, and lipidomics; World database access; and Response and clinical outcomes. AI-POWR™ allows for the selection of novel drug targets, biomarkers, and appropriate patient populations. AI-POWR™ is used to identify responders from big data sources using Hepion’s multi-omics approach, while modelling inputs and scenarios to increase response rates. The components of AI-POWR™ include access to publicly available databases, and in-house genomic and multi-omic big data, processed via machine learning algorithms. AI outputs allow for improved response outcomes through

Read More

Global Pulmonary Drug Delivery Systems Market Current Research Report And Unique Predictive Business Strategy By 2029

Pune, Maharashtra, India, September 28 2020 (Wiredrelease) Prudour Pvt. Ltd :Market.us delivers granular analysis of Pulmonary Drug Delivery Systems Market Business Challenges, Investment Opportunities, Demand, Key Manufacturers and 2029 Forecast Research Report, which includes global industry analysis, key market trends, vendor classification with their market positioning, sales, revenue and market share with the product type and by applications. Likewise, The development ratio which is expected in perspective of the rational analysis provides thorough information concerning contributions by way of top key vendors, demand, and deliver complete evaluation as well as market proportion boom of the Pulmonary Drug Delivery Systems industry.

Pulmonary Drug Delivery Systems Market: An Structure Overview

Pulmonary Drug Delivery Systems Market play a vital role in pharmaceuticals and healthcare industry. This intelligence report along with (2020-2029) Forecast of Pulmonary Drug Delivery Systems market study exhibits a pattern of interpreting previous data sources gathered from the most reliable

Read More

Global Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region: Trend Forecast and Growth Opportunity – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.

Global oral antibiotics market will reach $26.67 billion by 2030, growing by 4.0% annually over 2020-2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.

Highlighted with 89 tables and 97 figures, this 187-page report Global Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on

Read More

Diabetic Retinopathy Drug Market Analysis 2020-2025 by Technological Advancements, Business Analysis Top Companies, Demand Forecast

The MarketWatch News Department was not involved in the creation of this content.

Sep 21, 2020 (AmericaNewsHour) —
Diabetic retinopathy is a medical condition which damages retina (present at the back of eye) and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.

The global diabetic retinopathy drug market is anticipated to bolster at a robust growth rate to reach USD 705 Million by 2025. Geographically, the global diabetic retinopathy drug market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of World.

“The Final Report will cover the impact analysis of COVID-19 on this industry (Regional Market).”

Request To Fill The form for a Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10075281

Market Segmentation

By

Read More

Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities

SHANGHAI, Sept. 20, 2020 /PRNewswire/ — Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as “Viva Biotech” or “The Company”) entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interest in SYNthesis med chem (Hong Kong) Limited (hereinafter referred to as ” SYNthesis “), at the consideration of approximately US$ 80 million (equivalent to approximately HK$ 620 million). The acquisition will achieve the synergies between Viva Biotech and SYNthesis, regarding to the CRO business in the global market, which is of great strategic significance for The Company to conduct vertical integration and establish a comprehensive one-stop drug services platform.

SYNthesis is a preclinical small molecule drug discovery service contract organisation which mainly provides high-end pharmaceutical chemistry and synthetic chemistry services to its clients. SYNthesis is headquartered in Hong

Read More

Global Central Nervous System Diseases Drug Delivery Technologies, Markets & Companies Research Report 2020 – ResearchAndMarkets.com – Press Release

DUBLIN–(Business Wire)–The “Drug Delivery in Central Nervous System Diseases – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at

Read More

Diabetes Drug Market Demand Status 2020 Share, Global Trend, Industry News, Size, Business Growth, Top Key Players Update by Forecast to 2026

The MarketWatch News Department was not involved in the creation of this content.

Sep 18, 2020 (The Expresswire) —
Global “Diabetes Drug Market” report gives a historical overview of the Diabetes Drug market trends, growth, revenue, capacity, cost structure, and key driver’s analysis. The report further investigates and assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the Diabetes Drug market. Report covers the current status of the market including Internal Nasal Dilators market size, growth rate, prominent players, and current competitive landscape. It also analyses future opportunities and forecasts the market assessing the strategies of the key players in terms of merger and acquisitions, investments, technological advancements.

Get Sample PDF of the report at – https://www.marketreportsworld.com/enquiry/request-sample/15514002

● In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.

Read More

S.Africa’s Aspen sells thrombosis drug business to Mylan, shares jump

Adds details

JOHANNESBURG, Sept 8 (Reuters)South African drugmaker Aspen Pharmacare APNJ.J has agreed to sell the rights to its European thrombosis business to U.S. pharmaceutical company Mylan MYL.O for almost 642 million euros ($759 million), sending its shares up 7% on Tuesday.

“The transaction supports Aspen’s strategy of continuing to reshape the Group towards a greater concentration of revenue in emerging markets,” Aspen said in a statement.

The company said it would retain the thrombosis business almost exclusively in emerging markets.

The sale will also allow Aspen to streamline its business in Europe, strengthen its balance sheet and provide “financial headroom” for future investments, the company said.

Proceeds from the deal will be used to reduce the group’s debt, Aspen said, adding Mylan would pay 263.2 million euros on completion of the deal and the balance in June 2021.

Investors have been concerned about Aspen’s debt in

Read More